Abstract
Background and aims: An epidemiological retrospective study and a recent prospective study from Finland have both concluded that vitamin D3 supplementation at birth protects individuals from type 1 diabetes later in life. Moreover, it is thought that vitamin D3 supplementation, in particular its activated form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2 D3 ], may act as an immunomodulator, facilitating the shift from a Th1 to a Th2 immune response. The aim of this surveillance study was to measure levels of both 25-hydroxyvitamin D3 (25OHD3 ) and 1,25- dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes as compared to normal subjects. Methods: We measured plasma levels of 25-hydroxyvitamin D3 [25OHD3 ] and 1,25-dihydroxyvitamin D3 by radioimmunoassay in 88 consecutive patients with newly diagnosed type 1 diabetes (mean age 14.6 years; diagnosis within the last week), and in 57 healthy age and sex-matched subjects (mean age 16.5 years) born and residing in the Lazio region of continental Italy. Results: Mean levels of both 25OHD3 and 1,25-(OH)2 D3 were significantly lower in patients compared to controls (p < 0.01 and p < 0.03, respectively). There was no correlation between 1,25-(OH)2 D3 plasma level and metabolic control status at disease diagnosis, age, gender, or most importantly, seasonality of disease diagnosis. This new observation endorses the findings of the Finnish study, even though Italy is a geographic area with more hours of sunlight than Finland. Conclusions: These findings suggest that vitamin D3 may be an important pathogenic factor in type 1 diabetes independent of geographical latitude, and that its supplementation should be considered not only at birth, but also at diagnosis of type 1 diabetes with the aim of favouring a Th2 immune response and protecting residual beta cells from further destruction.
Key words
Vitamin D3
- type 1 diabetes - immune response
References
1
The EURODIAB Sub-study Group .
Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus.
Diabetologia.
1999;
42
51-54
2
Hypponen E, Läärä E, Reunanen A, Järvelin M R, Virtanen S M.
Intake of vitamin D and risk of type 1 diabetes: a birth cohort study.
The Lancet.
2001;
358
1500-1503
3
Cantorna M T.
Vitamin D and Autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence?.
Proc Soc Exp Biol Med.
2000;
223
230-233
4
Stene L C, Ulrikesen J, Magnus P, Joner G.
Use of cod liver oil during pregnancy associated with lower risk of type 1 diabetes in the offspring.
An J Clin Nutr.
2003;
78
1128-1134
5
Mathieu C, Adorini L.
The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents.
Trends Mol Med.
2002;
8
174-179
6
Lemire J.
1,25 dihydroxyvitamin D3 - a hormone with immunomodulatory properties.
J Rheumatol (Suppl 1).
2000;
59
24-27
7
Cantorna M T, Woodward B, Hayes C E, Deluca H F.
1,25dihydroxyvitamin D3 is a positive regulator for the two antiencephalitogenic cytokines TGF-β1 and IL-4.
J Immunol.
1998;
160
5314-5319
8
Riachy R, Vandewalle B, Kerr Conte J, Moerman E, Sacchetti P, Lukowiak B, Gmyr V, Bouckenooghe T, Dubois M, Pattou F.
1,25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20.
Endocrinology.
2002;
143
4809-4819
9
Casteels K, Waer M, Laureys J, Valckx D, Depovere J, Bouillon R, Mathieu C.
Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic non-obese diabetic mice by a combination of a vitamin D3 analog and cyclosporine.
Transplantation.
1998;
15
1225-1232
10
Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R.
Prevention of type 1 diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25dihydroxyvitamin D3, KH1060.
Endocrinology.
1995;
3
866-872
11
Casteels K M, Mathieu C, Waer M, Valckx D, Overbergh L, Laureys J M, Bouillon R.
Prevention of type 1 diabetes in non-obese diabetic mice by late intervention with non hypercalcemic analogs of 1,25dihydroxyvitamin D3 in combination with a short induction course of cyclosporin.
J Endocrinology.
1998;
1
95-102
12
McKinney P A.
Seasonality of birth in patients with childhood type 1 diabetes in 19 European regions.
Diabetologia.
2001;
44 Suppl 3
B67-B74
13
Baumgartl H J, Standl E, Schmidt-Gayk H, Kolb H J, Janka H U, Ziegler A G.
Changes of vitamin D serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus.
Diabetes Res.
1991;
16
145-148
14
Schneider L E, Schedl H P, McCain T, Haussler M R.
Experimental diabetes reduces circulating 1,25-dihydroxyvitamin D in the rat.
Science.
1997;
196
1452-1454
15
Ishida H, Seino Y, Tsuda K, Takemura J, Nishi S, Ishizuka S, Imura H.
Effects of streptozotocin-induced diabetes on circulating levels of vitamin D metabolites.
Acta Endocrinol (Copenh).
1983;
104
96-102
16
Verhaeghe J, van Bree R, van Herck E, Jans I, Zaman Z, Bouillon R.
Calciotrophic hormones during experimental hypocalcaemia and hypercalcaemia in spontaneously diabetic rats.
J Endocrinol.
1999;
162
251-258
17
EURODIAB ACE Study Group .
Variation and trends in incidence of childhood diabetes in Europe.
Lancet.
2000;
355
873-876
18
Pani M A, Knapp M, Donner H, Braun J, Baur M P, Usadel K H, Badenhoop K.
Vitamin D receptor allele combinations influence genetic susceptibility to type 1 diabetes in Germans.
Diabetes.
2000;
3
504-507
19
Akerblom H K, Vaarala O, Hyoty H, Ilonen J, Knip M.
Environmental factors in the etiology of type 1 diabetes.
Am J Med Genet.
2002;
30
18-29
20
Hawa M I, Valorani M G, Buckley L R, Beales P E, Afeltra A, Cacciapaglia F, Leslie R D, Pozzilli P.
Lack of effect of vitamin D administration during pregnancy and early life on diabetes incidence in the non-obese diabetic mouse.
Horm Metab Res.
2004;
36
620-624
Prof. Paolo Pozzilli
Dept. of Endocrinology and Diabetes · University Campus Bio-Medico
Via E Longoni, 83 · 00155 Rome · Italy
Phone: +39 (06) 22541 556
Fax: +39 (06) 22541 336
Email: p.pozzilli@unicampus.it